ProCE Banner Series

Driving Progress in HNSCC: Integrating Immunotherapy and Novel Targeted Therapies Across the Disease Continuum

Join us either in person or online for this interactive symposium in conjunction with AHNS 2025 in which a panel of experts will discuss the nuances of immunotherapy and targeted therapy for patients with head and neck squamous cell carcinoma (HNSCC).

This registration is for the virtual event only. To register for the in-person event, please visit: https://cosm.md/registration-information/

COSM does not endorse the views or information presented at these events. Accreditation for this event is provided separately from that of the conference.

  AMA
Who Should Attend

This activity has been designed to meet the educational needs of medical oncologists and other healthcare professionals involved in managing patients with HNSCC.

All Events

Driving Progress in HNSCC: Integrating Immunotherapy and Novel Targeted Therapies Across the Disease Continuum

Upcoming Events

May

15

2025

6:30 AM - 8:00 AM Central Time (CT)

Virtual

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners in effort to optimize treatment for patients with head and neck cancer.

Target Audience
This activity has been designed to meet the educational needs of medical oncologists and other healthcare professionals involved in managing patients with HNSCC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify patients with HNSCC most likely to benefit from immunotherapy using predictive and/or prognostic biomarkers
  • Design individualized treatment plans leveraging immunotherapy for patients with recurrent or metastatic HNSCC based on approvals, clinical data, guidelines, and patient factors
  • Evaluate emerging evidence for novel systemic therapies and their potential application to clinical practice for HNSCC
  • Formulate evidence-based strategies for monitoring and managing adverse events related to immunotherapy-based treatments for patients with HNSCC

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/67167f3d10da3.png

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

Supported by educational grants from Coherus BioSciences, Inc. and Merck Sharp & Dohme Corp.

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191